Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 85%
filed 2026-09-15
Item 8.01
BioMarin announced discontinuation of VOXZOGO development for children with Noonan syndrome, a clinical and strategic decision affecting the company's pipeline and future revenue prospects. While not a specific operational category (workforce reduction, restructuring, or material contract), this represents a material operational/strategic event—the termination of a development program—that would affect a reasonable investor's assessment of the company's product portfolio and growth trajectory. The company explicitly states this decision was not safety or efficacy related, suggesting it was driven by feasibility and market considerations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-15
Item 7.01
West Coast Community Bancorp announced that its Form 10 Registration Statement was declared effective by the SEC and its common stock was approved for listing on Nasdaq under ticker "WCCB," transitioning from OTCQX trading. This is a material operational and strategic milestone—the uplisting to a major national exchange enhances market visibility, liquidity, and access to institutional investors. While not a traditional M&A event, debt issuance, or earnings release, the uplisting represents a significant corporate development that would affect a reasonable investor's assessment of the company's market position and growth trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
Tianci International disclosed entry into a Memorandum of Understanding with BTC Digital Ltd. to cooperate on a crypto computing project targeting approximately 3 MW deployment within twelve months. While the MOU is explicitly non-binding and contemplates future definitive agreements, it represents a material strategic business initiative that extends the company's existing mining-equipment hosting arrangements into larger-scale computing infrastructure collaboration. This is an operational/strategic business event that does not fit the specific categories of M&A activity (no acquisition, merger, or change of control), debt issuance, or other named financial events, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
This news release announces the launch of VINIA Daily Chews, a new product format for BioHarvest's flagship consumer product VINIA. The disclosure describes a material product expansion and commercialization milestone—broadening the addressable market through a new delivery format, demonstrating the versatility of the Botanical Synthesis platform to prospective CDMO customers, and providing a pathway for customer acquisition and revenue growth. While not a discrete M&A, litigation, or financial event, this represents a significant operational and commercial development for the company's core consumer asset and CDMO strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
BioHarvest Sciences announced its dual listing on the Tel Aviv Stock Exchange (TASE) alongside its existing Nasdaq listing, with Common Shares beginning trading on TASE on September 8, 2026. This is a material operational and strategic event — a significant capital markets milestone involving listing on a major foreign exchange — but does not fit the specific event-type categories (not M&A, not a financial obligation, not governance-related in the traditional sense). The disclosure clearly affects investor assessment of the company's market access and strategic positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 45%
filed 2026-09-15
Item 1.01
The company entered into a material definitive agreement. Without access to the specific prose content, the exact nature of the agreement—whether operational, financial, or strategic—cannot be determined with certainty.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
SU Group announced the award of an exclusive distributorship for HDX's TRACELINE PX3 Portable X-Ray System in Hong Kong and Macau, described as the company's "second international distribution deal of 2026" and a strategic entry into the industrial inspection market. This is a material operational/commercial milestone—a new distribution partnership that expands the company's product portfolio and market reach—but does not fit the specific event categories (M&A, debt, equity issuance, etc.). The CEO's commentary emphasizes the strategic importance and margin potential, supporting materiality.
View raw filing on EDGAR →
8-K
Operational Other
confidence 78%
filed 2026-09-15
Item 8.01
ZEO ScientifiX announced a planned expansion into Georgia and Tennessee following enactment of new state laws establishing frameworks for stem cell and regenerative medicine therapies. This is a material operational and strategic business event—a geographic market expansion tied to new regulatory frameworks—that does not fit a specific named category. The expansion represents a significant growth initiative for the company's Southeast presence and business strategy, making it material to investors, but it is fundamentally an operational/strategic announcement rather than a financial transaction (M&A), governance matter, or other specialized event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
Connect Biopharma announced positive topline results from its Phase 2 Seabreeze STAT asthma study of rademikibart on September 15, 2026, showing statistically significant improvements in lung function (FEV1) and a 66% reduction in treatment failure rate, though the primary endpoint missed statistical significance. This material clinical milestone was disclosed via press release and represents a significant development in the company's pipeline progress and regulatory pathway.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
The filing discloses the launch of RAD's ROSA and RIO platforms on the Immix monitoring software platform following successful user acceptance testing and months of engineering work. This represents a material operational and strategic milestone—the completion of a significant product integration with a major third-party platform that enables deployment to "the nation's largest guarding and monitoring companies." While this is a product/partnership milestone rather than a specific named event type (M&A, litigation, financial obligation, etc.), it is clearly operational in nature and material to investors assessing the company's ability to commercialize its AI-driven security technologies and penetrate the enterprise security market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
Elemental announces its inclusion in the MVIS Global Junior Gold Miners Index (GDXJ), effective September 18, 2026, following the ETF's semi-annual review. The CEO characterizes this as "another important milestone" reflecting the company's transformation, increased scale, trading liquidity, and portfolio quality, with expected benefits to investor visibility and liquidity. While this is an operational/market-profile event rather than a discrete transaction or financial event, the inclusion in a major ETF ($9.3B in AUM) is material to a reasonable investor's assessment of the company's market positioning and accessibility to capital markets.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
Western Copper & Gold announces that its Casino Project has been selected for inclusion in the Canada Investment Summit Prospectus, a government-hosted forum designed to attract $1 trillion in new investment over five years. This is a strategic business development milestone recognizing Casino as "one of Canada's most significant investment opportunities" and placing it before global institutional investors. While not a discrete transaction (M&A, debt issuance, or earnings event), the selection represents material operational and strategic recognition that could facilitate project financing and advancement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
Gold X2 announces its inclusion in the VanEck Junior Gold Miners ETF (GDXJ) effective September 18, 2026, following the ETF's semi-annual review. The CEO states this "marks an important milestone" and will "further enhance our trading liquidity and reach among investors in both domestic and international markets." While this is an operational/strategic milestone rather than a discrete event like M&A, executive change, or financial restatement, inclusion in a major ETF is material to a reasonable investor as it affects market accessibility, liquidity, and investor base — factors that influence valuation and trading dynamics for a junior mining company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This corporate update discloses three operational milestones: (1) initiation of research coverage by Atrium; (2) receipt of first orders under a Government of Canada standing offer for ZenGUARD™ filtration products; and (3) bench-scale purification results for Albany Graphite achieving 5N+ purity (99.99985 wt.% carbon). While each element is operational rather than a discrete event type (not M&A, not a restatement, not an impairment), the combination—particularly the first commercial orders under a government standing offer and the achievement of certified high-purity graphite material for customer evaluation—represents material progress on the Company's critical minerals and commercialization strategy that would affect a reasonable investor's assessment of execution risk and near-term revenue potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 7.01
Armata announced that the FDA granted Breakthrough Therapy designation to AP-SA02, a clinical-stage bacteriophage therapeutic for complicated S. aureus bacteremia. This regulatory milestone—combined with the company's existing Fast Track and QIDP designations—represents material operational progress that accelerates the development pathway and validates the therapeutic approach. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory and regulatory prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) for treating spinal muscular atrophy in adults and children 2+ years old receiving SMN2-targeted therapy. This represents a major regulatory and commercial milestone—the first muscle-targeted treatment for SMA—with immediate U.S. commercial launch underway.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Definium announced positive topline results from the Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder, meeting primary and key secondary efficacy endpoints. This represents a material clinical milestone—the third positive Phase 3 trial for DT120 ODT and the second in GAD—with a planned pre-NDA meeting in 4Q 2026 and NDA filing anticipated in 1H 2027.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This exhibit is a monthly operational and capital allocation update disclosing August 2026 bitcoin mining production (44 BTC mined), hashrate metrics (10.05 EH/s non-JV, 4.92 EH/s JV), and a material capital allocation decision: the sale of all ETH holdings (3,952 ETH) and 54 BTC for ~$13.9M in proceeds, with $5.4M deployed to repurchase 13.6M ADSs. While the document includes routine operational metrics, the treasury monetization and share repurchase activity represent a discrete capital allocation event material to shareholders. This does not fit earnings_release (no comprehensive financial results), dividend_distribution (not a regular distribution), or dilutive_issuance (a buyback, not an issuance). The operational and capital-allocation nature makes operational_other the best fit.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
EX-99.1
This press release announces positive Phase 1 clinical trial results for AGMB-447 in IPF patients, including favorable safety/tolerability, robust target engagement, and the design and planned initiation of a Phase 2 study (INSPIRIA). While the company is clinical-stage and this represents a material clinical milestone advancing the lead program, it does not fit the discrete event categories (not an earnings release, M&A, executive change, or financial obligation). The disclosure is clearly operational—a clinical development milestone—but the specific type is not enumerated, making `operational_other` the appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 7.01
This Item 7.01 disclosure furnishes an investor presentation delivered by Executive Chairman Terence Cryan at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The presentation provides updates on Westwater's business plan, including progress on the Kellyton Graphite Plant (Phase 1 and Phase 2), the Coosa Graphite Deposit, permitting timelines, financing milestones (including a $25 million EXIM loan approval), and production catalysts. While the presentation is operational and strategic in nature rather than a discrete event like M&A, litigation, or financial restatement, it discloses material business developments and forward-looking guidance that would affect a reasonable investor's assessment of the company's prospects and execution timeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 7.01
The Company completed a previously announced 1-for-10 reverse stock split effective September 9, 2026, reducing outstanding shares from 52.6 million to 5.3 million and resulting in changes to the trading symbol and CUSIP.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
EX-99.1
Cellectis announced a strategic transformation approved by its board on September 11, 2026, to pivot from cell therapy (lasme-cel and eti-cel) to in vivo gene editing, with two lead programs (.HEAL-101 and .HEAL-201) advancing toward Phase 1 trials. The company is exiting lasme-cel and eti-cel development, realigning its operating model, and extending cash runway to H2 2028. This is a material strategic and operational restructuring affecting the company's pipeline, resource allocation, and financial trajectory, but does not fit the specific categories of M&A, workforce reduction (though implied), or other named event types—it is a comprehensive strategic pivot that is clearly operational in nature.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.2
TRX Gold was added to the MVIS® Global Junior Gold Miners Index (MVGDXJ) following the Q3 2026 rebalance, a development the CEO characterized as a major milestone expected to attract additional global institutional investment and increase liquidity through potential inclusion in related ETFs such as GDXJ.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
The exhibit announces a formal construction decision (FID) for the Cariboo Gold Project, a major operational and strategic milestone. While the disclosure includes financing components (US$30 million equity investment from Trafigura and a potential US$120 million prepayment facility), the principal event is the Board's approval to proceed with full-scale construction of the company's flagship project, with first gold pour expected in Q1 2029. This is a material operational/strategic decision that does not fit neatly into the specific event categories (not M&A, not a discrete financing event, not a periodic report), making it an operational_other event that would significantly affect investor assessment of the company's trajectory and capital deployment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This exhibit presents Legend Biotech's cell therapy pipeline portfolio, detailing the status of multiple programs across autologous, allogeneic, and in vivo therapies targeting oncology and autoimmune indications. The disclosure highlights clinical progress (e.g., CARVYKTI® patient follow-up post-NDA, multiple Phase II/III programs enrolling) and partnerships (Janssen/J&J collaboration, Novartis license agreement), which constitute material operational and strategic updates relevant to investors assessing the company's pipeline value and competitive positioning, though it does not constitute a discrete event like an approval, initiation, or termination.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
Evaxion announces expansion of its AI-Immunology™ platform into a new therapeutic area (autoimmune diseases) with two novel treatment concepts under experimental testing. This represents a material strategic expansion of the company's therapeutic focus and pipeline, with data to be presented at a major industry conference (PEGS Europe, November 18, 2026). While not a discrete M&A, financing, or personnel event, this disclosure of a significant new therapeutic direction and experimental validation milestone would affect a reasonable investor's assessment of the company's strategic positioning and pipeline diversification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
TransAlta's subsidiary received a U.S. Department of Energy order mandating that Centralia Unit 2 remain available for operation for 90 days through December 12, 2026. This is a regulatory directive affecting operational status of a material asset. While not fitting a discrete named category (not a contract, partnership, or restructuring), it is clearly an operational/regulatory event material to investors assessing the company's generation capacity and compliance obligations. The 90-day mandate represents a significant operational constraint imposed by federal authority.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This press release announces the technical details and advancement of HPDI 3.0, the next-generation fuel system from Cespira (Westport's joint venture with Volvo Group). The disclosure highlights product enhancements, performance improvements, and production timeline (Q4 2026 start, early 2027 deployment). While this is a material product announcement affecting Westport's competitive positioning and market prospects, it does not fit the discrete event categories (no M&A, no earnings results, no executive changes, no impairment). The mention of Cespira's 125% revenue growth year-over-year is contextual but not the primary disclosure. This is best classified as an operational/strategic business milestone—a material product advancement and market development announcement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.2
NOVONIX announced progress in customer qualification for its synthetic graphite anode material, with the lead customer's testing meeting 12 of 14 specifications and the company identifying corrective actions for the two near-misses, representing a material milestone toward commercial production and mass production sales beginning in H2 2027.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda® in FAP-α positive solid tumors. This is a material strategic partnership involving a Phase 1/2a clinical trial amendment with a major pharmaceutical company providing drug supply at no cost. While this is clearly an operational/strategic business event, it does not fit the specific categories of M&A activity, debt issuance, or other named financial/legal events. The collaboration represents a significant clinical development milestone and partnership that would affect investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-14
Item 8.01
Corbus Pharmaceuticals announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment, demonstrating statistically significant weight loss (5% at 60 mg dose) and favorable safety profile, with data selected for late-breaking presentation at ObesityWeek® 2026. This material clinical development milestone affects investor assessment of the company's lead obesity program's development trajectory and commercial potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 7.01
FrontView REIT released investor update slides for real estate investor conferences disclosing portfolio metrics, acquisition/disposition activity, capital structure, and financial guidance. While the slides contain operational and financial data (acquisitions of $119.3M YTD, dispositions of $46.8M YTD, AFFO per share guidance, and portfolio composition), this is a Regulation FD disclosure furnished for informational purposes at investor conferences rather than a material event triggering a specific 8-K category. The disclosure is operational in nature—presenting business performance and strategic positioning—but does not constitute earnings release, M&A completion, guidance change, or other discrete material event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Cullinan Therapeutics announced positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median progression-free survival benefit (14.5 vs. 8.5 months; HR 0.50; P=0.00015) in first-line EGFR exon 20 insertion mutation NSCLC. This material clinical milestone supports potential regulatory advancement and commercialization of a key pipeline asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
EX-99.1
This exhibit is an operational and guidance update from Obsidian Energy disclosing revised 2026 production guidance (28,500–29,500 boe/d, down from 29,000–31,000 boe/d) due to weather-related development delays and third-party facility downtime at recently acquired Belly River assets. The update includes detailed capital program progress, well drilling activity, infrastructure development, and forward-looking 2027 production targets of 15%+ growth. While it contains financial metrics and forward guidance, the primary substance is operational—drilling programs, asset integration, and production outlook—rather than a discrete financial event (earnings release, debt issuance, M&A completion) or governance matter. This is a material operational disclosure affecting investor assessment of production trajectory and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Sionna announced plans to advance SION-451 + SION-2222 into Phase 2a clinical trials based on post hoc analysis of prior trial data, a material strategic milestone for the clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
EX-99.1
This press release announces enrollment of the first patients with Alcohol Use Disorder in Clearmind's CMND-100 clinical trial, representing a material clinical development milestone. The disclosure describes a significant operational and strategic advancement in the company's drug development program—the transition from healthy-volunteer studies to patient enrollment—which would affect a reasonable investor's assessment of the company's progress toward commercialization and value creation. While not fitting a discrete named event type, this is clearly a material operational/clinical milestone for a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This announcement discloses positive interim Phase 2b clinical trial data for RAD101 (93% concordance with MRI, meeting primary endpoint) and selection for late-breaking oral presentation at SNO26, along with a planned FDA meeting to align on Phase 3 protocol. While the data is clinically significant and material to investors assessing the company's pipeline progress, it does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). This is a material clinical/regulatory milestone in drug development—an operational event reflecting advancement toward pivotal trials in a ~$600M addressable market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
Psyence BioMed announced the formation of Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary designed to coordinate ibogaine development, manufacturing, regulatory engagement, and potential clinical activities. This is a material operational and strategic restructuring—establishing a dedicated U.S. vehicle to hold U.S. rights to pharmaceutical-grade ibogaine from PsyLabs (subject to definitive licensing), coordinate supply and manufacturing, and serve as the counterparty for federal agencies and clinical partners. While not a discrete M&A transaction, the creation of this subsidiary and the intended licensing arrangement represent a significant strategic repositioning to advance the company's U.S. ibogaine program in response to recent federal policy developments (Executive Order of April 18, 2026, and coordinated federal implementation in July 2026).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
This press release announces a follow-on production order from an Asia-based Tier-1 robotics customer for Mobilicom's Mobile Ground Control Stations. The disclosure highlights a material commercial milestone—a repeat order from a major customer across multiple product families—that demonstrates market traction and revenue-generating activity. While not a discrete M&A transaction, debt issuance, or earnings announcement, this represents a material operational/commercial event that would affect a reasonable investor's assessment of the company's business momentum and customer relationships in the robotics sector.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-14
Item 1.01
Treasure Global entered into a $2,000,000 Software Development Agreement with Mestiz Technology to build a centralized Power BI business intelligence platform across three business environments, representing a material strategic investment in the company's data analytics infrastructure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Item 8.01
Allarity announced that its newly formed subsidiary, Allarity Acquisition Corp. (a SPAC), has filed a Registration Statement on Form S-1 for a proposed $100–$115 million initial public offering. This is a material capital allocation and strategic business event—the creation and public offering of a subsidiary SPAC—that would affect a reasonable investor's assessment of the company's capital structure and strategic direction. While the SPAC itself is a separate entity, Allarity's sponsorship (via ALLR Sponsor LLC owning ~25% post-offering) and the diversion of management resources constitute a material operational and strategic disclosure. This does not fit neatly into the specific categories (not M&A activity, not a debt issuance, not a dilutive equity issuance by Allarity itself), so operational_other is the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
60 Degrees Pharmaceuticals disclosed submission of a Statement of Interest to the FDA requesting a Commissioner's National Priority Voucher (CNPV) for an efficacy supplement to support potential FDA approval of tafenoquine for babesiosis treatment. This is a material regulatory and strategic milestone—the CNPV could accelerate approval timelines and enable the first FDA-approved babesiosis therapy. While the filing emphasizes clinical efficacy signals and regulatory pathway, the core disclosed event is a strategic regulatory filing that would materially affect the company's development timeline and commercial prospects, fitting operational_other as a material business development event not captured by more specific categories.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-14
EX-99.1
First Mining announces its inclusion in the MVIS Global Junior Gold Miners Index (MVGDXJ) and the VanEck Junior Gold Miners ETF (GDXJ), effective September 18, 2026. The company states this will "enhance visibility among institutional and retail investors, improve trading liquidity, and increase exposure to global capital markets." While this is a capital-markets and investor-relations milestone rather than a discrete operational or financial event (not earnings, M&A, debt, or governance), it is material to investors as it affects market accessibility and liquidity for the stock. The event does not fit a named category but is clearly operational/strategic in nature.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
The exhibit announces FDA acceptance of a New Drug Application (NDA) under Priority Review for Takeda's investigational drug zasocitinib for moderate-to-severe plaque psoriasis, with a PDUFA target action date in Q1 2027. This is a material regulatory milestone in the drug development pipeline—a significant operational and strategic event for a biopharmaceutical company—but does not fit the specific event types for earnings, M&A, executive changes, or financial obligations. The announcement discloses Phase 3 clinical trial results supporting the NDA and represents progress toward potential commercialization of a next-generation therapeutic candidate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-14
Item 8.01
Phio announced submission of a comprehensive briefing package to the FDA following completion of a Phase 1b clinical trial for PH-762, with plans for a Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing progress in regulatory engagement and advancement toward the next phase of clinical development. While not a specific earnings release, M&A activity, or governance event, this operational/strategic milestone would affect a reasonable investor's assessment of the company's pipeline progress and regulatory trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Lipocine announced initiation of the BLOOM Phase 3 clinical trial for LPCN 1154 in postpartum depression treatment. This is a material operational and clinical development milestone for a biopharmaceutical company, representing advancement toward potential regulatory submission and commercialization. The disclosure includes study design, enrollment targets, timing, and cash requirements, all of which would affect investor assessment of the company's pipeline progress and capital allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Soluna announced that ERCOT has conditionally classified its 100 MW Project Dorothy campus as Base Load in Batch Zero, a regulatory milestone that preserves interconnection capacity and exempts the project from further reliability evaluation. This is a material operational and regulatory achievement for the company's data center development strategy, though it is conditional pending ERCOT's verification process. The disclosure does not fit neatly into specific categories like M&A, debt issuance, or earnings, but represents a significant operational/strategic milestone for the company's renewable energy infrastructure business.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-14
Telomir disclosed preclinical research findings from The Ohio State University demonstrating that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models, and announced a strategic dual-pathway development approach: advancing its lead TNBC program toward Phase 1/2 enrollment while assessing a potential in vivo efficacy study in canine osteosarcoma. This is a material operational/strategic disclosure of research progress and development pathway expansion for a clinical-stage biotech company, but does not fit the specific categories of earnings release, M&A, litigation, or other named event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-14
EX-99.1
Nasus Pharma announced FDA clearance of its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis treatment, and plans to initiate a pivotal clinical study in Q4 2026 with topline data expected in Q1 2027. This is a material regulatory and clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress toward commercialization of a lead product candidate in a $2 billion market. While not fitting the specific event types (not an earnings release, M&A activity, or executive change), this operational/regulatory milestone would materially affect a reasonable investor's assessment of the company's development pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-14
The filing discloses a press release announcing Bitmine's cryptocurrency holdings (5.96 million ETH tokens valued at approximately $15.8 billion in total crypto and cash holdings), staking operations generating projected annualized revenues of $334 million, and progress toward the "Alchemy of 5%" goal of acquiring 5% of total ETH supply. While the disclosure includes forward-looking statements about digital asset strategy and market performance, the core event is an operational update regarding the company's treasury holdings, staking infrastructure (MAVAN), and strategic digital asset accumulation—a material operational and strategic business event that does not fit a specific named category but is clearly operational in nature.
View raw filing on EDGAR →